Metastatic potential differs across therapeutic groups, and the location and receptor status of tumor(s) at the first site of metastasis have important consequences on the spatiotemporal progression of the disease.6 How dysregulation of the classical receptors (ESR1 and ERBB2) relates to mechanisms driving metastasis including CSC activity and immune modulation remains to be fully understood. Here, ERBB2 is linked to neoplasm.